[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Download PDF
Figure.
Cumulative risk of cardiovascular events stratified by the presence or absence of generalized anxiety disorder in an age-adjusted model (A) and in a model fully adjusted for potential confounders and mediators (B) in 767 participants with complete data on all covariates.

Cumulative risk of cardiovascular events stratified by the presence or absence of generalized anxiety disorder in an age-adjusted model (A) and in a model fully adjusted for potential confounders and mediators (B) in 767 participants with complete data on all covariates.

Table 1. 
Baseline Characteristics of 1015 Participants With Stable Coronary Heart Disease by Generalized Anxiety Disorder Statusa
Baseline Characteristics of 1015 Participants With Stable Coronary Heart Disease by Generalized Anxiety Disorder Statusa
Table 2. 
Cardiovascular Events During Follow-up by Generalized Anxiety Disorder Status
Cardiovascular Events During Follow-up by Generalized Anxiety Disorder Status
Table 3. 
Change in the Strength of Association Between Generalized Anxiety Disorder and Cardiovascular Eventsa After Adjustment for Potential Confounders and Mediators
Change in the Strength of Association Between Generalized Anxiety Disorder and Cardiovascular Eventsa After Adjustment for Potential Confounders and Mediators
Table 4. 
Association Between Generalized Anxiety Disorder and Subsequent Cardiovascular Eventsa With Sequential Adjustment for Potential Confounders and Mediators
Association Between Generalized Anxiety Disorder and Subsequent Cardiovascular Eventsa With Sequential Adjustment for Potential Confounders and Mediators
Table 5. 
Fully Adjusted Model of the Association Between Generalized Anxiety Disorder and Subsequent Cardiovascular Eventsa in 767 Participants With Complete Data on All Covariates
Fully Adjusted Model of the Association Between Generalized Anxiety Disorder and Subsequent Cardiovascular Eventsa in 767 Participants With Complete Data on All Covariates
1.
Brotman  DJGolden  SHWittstein  IS The cardiovascular toll of stress. Lancet 2007;370 (9592) 1089- 1100
PubMedArticle
2.
Rosengren  AHawken  SOunpuu  SSliwa  KZubaid  MAlmahmeed  WABlackett  KNSitthi-amorn  CSato  HYusuf  SINTERHEART investigators, Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364 (9438) 953- 962
PubMedArticle
3.
Moussavi  SChatterji  SVerdes  ETandon  APatel  VUstun  B Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370 (9590) 851- 858
PubMedArticle
4.
Rugulies  R Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med 2002;23 (1) 51- 61
PubMedArticle
5.
Wulsin  LRSingal  BM Do depressive symptoms increase the risk for the onset of coronary disease? a systematic quantitative review. Psychosom Med 2003;65 (2) 201- 210
PubMedArticle
6.
Barth  JSchumacher  MHerrmann-Lingen  C Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004;66 (6) 802- 813
PubMedArticle
7.
van Melle  JPde Jonge  PSpijkerman  TATijssen  JGOrmel  Jvan Veldhuisen  DJvan den Brink  RHvan den Berg  MP Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66 (6) 814- 822
PubMedArticle
8.
Carney  RMFreedland  KEJaffe  AS Depression as a risk factor for coronary heart disease mortality. Arch Gen Psychiatry 2001;58 (3) 229- 230
PubMedArticle
9.
Denollet  JBrutsaert  DL Personality, disease severity, and the risk of long-term cardiac events in patients with decreased ejection fraction after myocardial infarction. Circulation 1998;97 (2) 167- 173
PubMedArticle
10.
Thombs  BDBass  EBFord  DEStewart  KJTsilidis  KKPatel  UFauerbach  JABush  DEZiegelstein  RC Prevalence of depression in survivors of acute myocardial infarction: review of the evidence. J Gen Intern Med 2006;21 (1) 30- 38
PubMedArticle
11.
Grace  SLAbbey  SEIrvine  JShnek  ZMStewart  DE Prospective examination of anxiety persistence and its relationship to cardiac symptoms and recurrent cardiac events. Psychother Psychosom 2004;73 (6) 344- 352
PubMedArticle
12.
Frasure-Smith  NLespérance  FTalajic  M Depression and 18-month prognosis after myocardial infarction [published correction appears in Circulation. 1998 Feb 24;97(7):708]. Circulation 1995;91 (4) 999- 1005
PubMedArticle
13.
Frasure-Smith  NLespérance  FTalajic  M The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol 1995;14 (5) 388- 398
PubMedArticle
14.
Lane  DCarroll  DRing  CBeevers  DGLip  GY Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001;63 (2) 221- 230
PubMedArticle
15.
Mayou  RAGill  DThompson  DRDay  AHicks  NVolmink  JNeil  A Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000;62 (2) 212- 219
PubMedArticle
16.
Sullivan  MDLaCroix  AZBaum  CGrothaus  LCKaton  WJ Functional status in coronary artery disease: a one-year prospective study of the role of anxiety and depression. Am J Med 1997;103 (5) 348- 356
PubMedArticle
17.
Sullivan  MDLaCroix  ZASpertus  JAHecht  J Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease. Am J Cardiol 2000;86 (10) 1135- 1138, A6, A9
PubMedArticle
18.
Rothenbacher  DHahmann  HWüsten  BKoenig  WBrenner  H Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links. Eur J Cardiovasc Prev Rehabil 2007;14 (4) 547- 554
PubMedArticle
19.
Shibeshi  WAYoung-Xu  YBlatt  CM Anxiety worsens prognosis in patients with coronary artery disease. J Am Coll Cardiol 2007;49 (20) 2021- 2027
PubMedArticle
20.
Moser  DKRiegel  BMcKinley  SDoering  LVAn  KSheahan  S Impact of anxiety and perceived control on in-hospital complications after acute myocardial infarction. Psychosom Med 2007;69 (1) 10- 16
PubMedArticle
21.
Frasure-Smith  NLespérance  F Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 2008;65 (1) 62- 71
PubMedArticle
22.
Lane  DCarroll  DRing  CBeevers  DGLip  GY Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. J Psychosom Res 2000;49 (4) 229- 238
PubMedArticle
23.
Lane  DCarroll  DRing  CBeevers  DGLip  GY Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction? QJM 2000;93 (11) 739- 744
PubMedArticle
24.
Lane  DCarroll  DRing  CBeevers  DGLip  GY In-hospital symptoms of depression do not predict mortality 3 years after myocardial infarction. Int J Epidemiol 2002;31 (6) 1179- 1182
PubMedArticle
25.
Ketterer  MWHuffman  JLumley  MAWassef  SGray  LKenyon  LKraft  PBrymer  JRhoads  KLovallo  WRGoldberg  AD Five-year follow-up for adverse outcomes in males with at least minimally positive angiograms: importance of “denial” in assessing psychosocial risk factors. J Psychosom Res 1998;44 (2) 241- 250
PubMedArticle
26.
Herrmann  CBrand-Driehorst  SBuss  URüger  U Effects of anxiety and depression on 5-year mortality in 5057 patients referred for exercise testing. J Psychosom Res 2000;48 (4-5) 455- 462
PubMedArticle
27.
Whooley  MAde Jonge  PVittinghoff  EOtte  CMoos  RCarney  RMAli  SDowray  SNa  BFeldman  MDSchiller  NBBrowner  WS Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300 (20) 2379- 2388
PubMedArticle
28.
Robins  LNHelzer  JCroughan  JRatcliff  K National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. Arch Gen Psychiatry 1981;38 (4) 381- 389
PubMedArticle
29.
Greist  JHKlein  MHErdman  HPBires  JKBass  SMMachtinger  PEKresge  DG Comparison of computer- and interviewer-administered versions of the Diagnostic Interview Schedule. Hosp Community Psychiatry 1987;38 (12) 1304- 1311
PubMed
30.
Blouin  AGPerez  ELBlouin  JH Computerized administration of the Diagnostic Interview Schedule. Psychiatry Res 1988;23 (3) 335- 344
PubMedArticle
31.
Dawson  DAGrant  BFStinson  FS The AUDIT-C: screening for alcohol use disorders and risk drinking in the presence of other psychiatric disorders. Compr Psychiatry 2005;46 (6) 405- 416
PubMedArticle
32.
Gehi  AKAli  SNa  BWhooley  MA Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med 2007;167 (16) 1798- 1803
PubMedArticle
33.
Bowles  HRFitzGerald  SJMorrow  JR  JrJackson  AWBlair  SN Construct validity of self-reported historical physical activity. Am J Epidemiol 2004;160 (3) 279- 286
PubMedArticle
34.
Kurtze  NRangul  VHustvedt  BEFlanders  WD Reliability and validity of self-reported physical activity in the Nord-Trondelag Health Study: HUNT 1. Scand J Public Health 2008;36 (1) 52- 61
PubMedArticle
35.
Ainsworth  BEJacobs  DR  JrLeon  AS Validity and reliability of self-reported physical activity status: the Lipid Research Clinics questionnaire. Med Sci Sports Exerc 1993;25 (1) 92- 98
PubMedArticle
36.
Aadahl  MKjaer  MKristensen  JHMollerup  BJørgensen  T Self-reported physical activity compared with maximal oxygen uptake in adults. Eur J Cardiovasc Prev Rehabil 2007;14 (3) 422- 428
PubMedArticle
37.
Jackson  AWMorrow  JR  JrBowles  HRFitzGerald  SJBlair  SN Construct validity evidence for single-response items to estimate physical activity levels in large sample studies. Res Q Exerc Sport 2007;78 (2) 24- 31
PubMedArticle
38.
Gehi  AMangano  DPipkin  SBrowner  WSWhooley  MA Depression and heart rate variability in patients with stable coronary heart disease: findings from the Heart and Soul Study. Arch Gen Psychiatry 2005;62 (6) 661- 666
PubMedArticle
39.
Otte  CMarmar  CRPipkin  SSMoos  RBrowner  WSWhooley  MA Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 2004;56 (4) 241- 247
PubMedArticle
40.
Otte  CNeylan  TCPipkin  SSBrowner  WSWhooley  MA Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005;162 (11) 2139- 2145
PubMedArticle
41.
Wulsin  LRMusselman  DOtte  CBruce  EAli  SWhooley  MA Depression and whole blood serotonin in patients with coronary heart disease from the Heart and Soul Study. Psychosom Med 2009;71 (3) 260- 265
PubMedArticle
42.
Whooley  MACaska  CMHendrickson  BERourke  MAHo  JAli  S Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry 2007;62 (4) 314- 320
PubMedArticle
43.
Ali  SGarg  SKCohen  BEBhave  PHarris  WSWhooley  MA Association between omega-3 fatty acids and depressive symptoms among patients with established coronary artery disease: data from the Heart and Soul Study. Psychother Psychosom 2009;78 (2) 125- 127
PubMedArticle
44.
Ren  XRistow  BNa  BAli  SSchiller  NBWhooley  MA Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol 2007;99 (12) 1643- 1647
PubMedArticle
45.
Asplund  KBonita  RKuulasmaa  KRajakangas  AMSchaedlich  HSuzuki  KThorvaldsen  PTuomilehto  JWorld Health Organization Monitoring Trends and Determinants in Cardiovascular Disease, Multinational comparisons of stroke epidemiology: evaluation of case ascertainment in the WHO MONICA Stroke Study. Stroke 1995;26 (3) 355- 360
PubMedArticle
46.
Thorvaldsen  PAsplund  KKuulasmaa  KRajakangas  AMSchroll  MWorld Health Organization Monitoring Trends and Determinants in Cardiovascular Disease, Stroke incidence, case fatality, and mortality in the WHO MONICA project. Stroke 1995;26 (3) 361- 367
PubMedArticle
47.
Luepker  RVApple  FSChristenson  RHCrow  RSFortmann  SPGoff  DGoldberg  RJHand  MMJaffe  ASJulian  DGLevy  DManolio  TMendis  SMensah  GPajak  APrineas  RJReddy  KSRoger  VLRosamond  WDShahar  ESharrett  ARSorlie  PTunstall-Pedoe  HAHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute, Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108 (20) 2543- 2549
PubMedArticle
48.
Thygesen  KAlpert  JSWhite  HDJaffe  ASApple  FSGalvani  MKatus  HANewby  LKRavkilde  JChaitman  BClemmensen  PMDellborg  MHod  HPorela  PUnderwood  RBax  JJBeller  GABonow  RVan der Wall  EEBassand  JPWijns  WFerguson  TBSteg  PGUretsky  BFWilliams  DOArmstrong  PWAntman  EMFox  KAHamm  CWOhman  EMSimoons  MLPoole-Wilson  PAGurfinkel  EPLopez-Sendon  JLPais  PMendis  SZhu  JRWallentin  LCFernández-Avilés  FFox  KMParkhomenko  ANPriori  SGTendera  MVoipio-Pulkki  LMVahanian  ACamm  AJDe Caterina  RDean  VDickstein  KFilippatos  GFunck-Brentano  CHellemans  IKristensen  SDMcGregor  KSechtem  USilber  STendera  MWidimsky  PZamorano  JLMorais  JBrener  SHarrington  RMorrow  DLim  MMartinez-Rios  MASteinhubl  SLevine  GNGibler  WBGoff  DTubaro  MDudek  DAl-Attar  NJoint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Universal definition of myocardial infarction. Circulation 2007;116 (22) 2634- 2653
PubMedArticle
49.
Baron  RMKenny  DA The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51 (6) 1173- 1182
PubMedArticle
50.
Maldonado  GGreenland  S Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138 (11) 923- 936
PubMed
51.
Grippo  AJJohnson  AK Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002;26 (8) 941- 962
PubMedArticle
52.
Thayer  JFFriedman  BHBorkovec  TD Autonomic characteristics of generalized anxiety disorder and worry. Biol Psychiatry 1996;39 (4) 255- 266
PubMedArticle
53.
Martens  EJNyklícek  ISzabó  BMKupper  N Depression and anxiety as predictors of heart rate variability after myocardial infarction. Psychol Med 2008;38 (3) 375- 383
PubMed
54.
Watkins  LLBlumenthal  JACarney  RM Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction. Am Heart J 2002;143 (3) 460- 466
PubMedArticle
55.
Cohen  HBenjamin  J Power spectrum analysis and cardiovascular morbidity in anxiety disorders. Auton Neurosci 2006;128 (1-2) 1- 8
PubMedArticle
56.
Cameron  OGNesse  RM Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology 1988;13 (4) 287- 307
PubMedArticle
57.
Cameron  OGSmith  CBLee  MAHollingsworth  PJHill  EMCurtis  GC Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 1990;28 (1) 3- 20
PubMedArticle
58.
Williams  RBMarchuk  DAGadde  KMBarefoot  JCGrichnik  KHelms  MJKuhn  CMLewis  JGSchanberg  SMStafford-Smith  MSuarez  ECClary  GLSvenson  IKSiegler  IC Central nervous system serotonin function and cardiovascular responses to stress. Psychosom Med 2001;63 (2) 300- 305
PubMedArticle
59.
Pitsavos  CPanagiotakos  DBPapageorgiou  CTsetsekou  ESoldatos  CStefanadis  C Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006;185 (2) 320- 326
PubMedArticle
60.
Benninghoven  DKaduk  AWiegand  USpecht  TKunzendorf  SJantschek  G Influence of anxiety on the course of heart disease after acute myocardial infarction: risk factor or protective function? Psychother Psychosom 2006;75 (1) 56- 61
PubMedArticle
61.
Zimmerman  MMcDermut  WMattia  JI Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 2000;157 (8) 1337- 1340
PubMedArticle
62.
Katon  WLin  EHBKroenke  K The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29 (2) 147- 155
PubMedArticle
63.
Aina  YSusman  JL Understanding comorbidity with depression and anxiety disorders. J Am Osteopath Assoc 2006;106 (5) (suppl 2)S9- S14
PubMed
64.
Walke  LMByers  ALGallo  WTEndrass  JFried  TR The association of symptoms with health outcomes in chronically ill adults. J Pain Symptom Manage 2007;33 (1) 58- 66
PubMedArticle
65.
Marchioli  RBarzi  FBomba  EChieffo  CDi Gregorio  DDi Mascio  RFranzosi  MGGeraci  ELevantesi  GMaggioni  APMantini  LMarfisi  RMMastrogiuseppe  GMininni  NNicolosi  GLSantini  MSchweiger  CTavazzi  LTognoni  GTucci  CValagussa  FGISSI-Prevenzione Investigators, Early protection against sudden death by n–3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) – prevenzione. Circulation 2002;105 (16) 1897- 1903
PubMedArticle
66.
Yokoyama  MOrigasa  HMatsuzaki  MMatsuzawa  YSaito  YIshikawa  YOikawa  SSasaki  JHishida  HItakura  HKita  TKitabatake  ANakaya  NSakata  TShimada  KShirato  KJapan EPA Lipid Intervention Study (JELIS) Investigators, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [published correction appears in Lancet. 2007;370(9583):220]. Lancet 2007;369 (9567) 1090- 1098
PubMedArticle
Original Article
July 2010

Scared to Death? Generalized Anxiety Disorder and Cardiovascular Events in Patients With Stable Coronary Heart DiseaseThe Heart and Soul Study

Author Affiliations

Author Affiliations: Department of Medical Psychology, Tilburg University, Tilburg (Drs Martens and de Jonge), Department of Psychiatry, University of Groningen, Groningen (Dr de Jonge), the Netherlands; Section of General Internal Medicine, VA Medical Center, San Francisco, California (Ms Na and Drs Cohen and Whooley); Department of Medicine, University of California, San Francisco (Drs Cohen and Whooley); and Department of Psychology, University of California, Irvine (Dr Lett).

Arch Gen Psychiatry. 2010;67(7):750-758. doi:10.1001/archgenpsychiatry.2010.74
Abstract

Context  Anxiety is common in patients with coronary heart disease (CHD), but studies examining the effect of anxiety on cardiovascular prognosis and the role of potential mediators have yielded inconsistent results.

Objectives  To evaluate the effect of generalized anxiety disorder (GAD) on subsequent cardiovascular events and the extent to which this association is explained by cardiac disease severity and potential behavioral or biological mediators.

Design  Prospective cohort study (Heart and Soul Study).

Setting  Participants were recruited between September 11, 2000, and December 20, 2002, from 12 outpatient clinics in the San Francisco Bay Area and were followed up until March 18, 2009.

Participants  One thousand fifteen outpatients with stable CHD followed up for a mean (SD) of 5.6 (1.8) years.

Main Outcome Measures  We determined the presence of GAD using the Diagnostic Interview Schedule. Proportional hazards models were used to evaluate the association of GAD with subsequent cardiovascular events and the extent to which this association was explained by potential confounders and mediators.

Results  A total of 371 cardiovascular events occurred during 5711 person-years of follow-up. The age-adjusted annual rate of cardiovascular events was 9.6% in the 106 participants with GAD and 6.6% in the 909 participants without GAD (P = .03). After adjustment for demographic characteristics, comorbid conditions (including major depressive disorder), cardiac disease severity, and medication use, GAD remained associated with a 62% higher rate of cardiovascular events (hazard ratio, 1.62; 95% confidence interval, 1.11-2.37; P = .01). Additional adjustment for a variety of potential behavioral and biological mediators had little effect on this association (hazard ratio, 1.74; 95% confidence interval, 1.13-2.67; P = .01).

Conclusions  In outpatients with CHD, a robust association between GAD and cardiovascular events was found that could not be explained by disease severity, health behaviors, or biological mediators. How GAD leads to poor cardiovascular outcomes deserves further study.

Ample evidence has demonstrated a strong and consistent association between psychological factors, such as stress and cardiovascular health.1,2 These factors are important contributors to health decrements in initially healthy patients and in patients with established coronary heart disease (CHD).3 Efforts have been made to understand how these factors contribute to CHD onset, progression, and prognosis. Most of these efforts have been directed toward depression, with several meta-analyses demonstrating that depression is an independent risk factor for the development of CHD in the general population4,5 and a prognostic risk factor in patients with CHD.6,7 It is less clear whether this increased risk of cardiac events extends to patients with other symptoms of negative affect, such as anxiety.8,9

Compared with the extensive literature on depression in patients with CHD, relatively few studies have examined the role of anxiety. Symptoms of anxiety are common in patients with CHD, with prevalence rates ranging from 24% to 31%.1015 Several studies14,16,17 have found that anxiety symptoms are predictive of disability, increased physical symptoms, and worse functional status and quality of life in patients with CHD. However, studies examining anxiety as a risk factor for future CHD events have yielded conflicting results. Some studies have reported anxiety symptoms to be predictive of subsequent cardiac events, mortality, and in-hospital complications11,1821 in patients with CHD, whereas others have found no association15,2224 or even a protective effect.25,26 In addition, the extent to which this increased risk is independent of potential confounding factors and the role of potential mediators has not been determined. Moreover, only 1 previous study21 has evaluated the cardiac prognostic importance of generalized anxiety disorder (GAD); others have relied on self-report measurement of anxiety symptoms. GAD is common and treatable and could, therefore, be an important modifiable risk factor in patients with CHD.

In a prospective cohort study of 1015 participants with stable CHD, we evaluated the independent effect of GAD on subsequent cardiovascular events and the extent to which this association was explained by differences in demographic characteristics, comorbid conditions, cardiac disease severity, and potential behavioral and biological mediators.

METHODS

The Heart and Soul Study was designed to determine how psychological disorders lead to cardiovascular events in outpatients with stable CHD.27 Patients in California were recruited from 2 Department of Veterans Affairs (VA) medical centers (San Francisco VA Medical Center and the VA Palo Alto Health Care System), 1 university medical center (University of California, San Francisco), and 9 public health clinics in the Community Health Network of San Francisco. Patients were eligible to participate if they had at least 1 of the following: a history of myocardial infarction, angiographic evidence of at least 50% stenosis in 1 or more coronary vessels, previous evidence of exercise-induced ischemia using treadmill or nuclear testing, a history of coronary revascularization, or a diagnosis of CHD documented by an internist or cardiologist. Between September 11, 2000, and December 20, 2002, a total of 1024 participants were enrolled: 240 from the public health clinics, 346 from the university medical center, and 438 from the VA medical centers.

All the participants completed a baseline examination that included an interview, fasting venous blood sample collection, a psychiatric interview, a questionnaire, echocardiography, exercise treadmill testing, 24-hour ambulatory electrocardiography, and 24-hour urine collection. Of the 1024 participants who completed the baseline examination, 3 did not complete the diagnostic interview for anxiety, and we could not contact 6 individuals (<1%) during follow-up, leaving 1015 for this analysis. The protocol was approved by the appropriate institutional review boards (Committee on Human Research, University of California, San Francisco; Research and Development Committee, VA Medical Center, San Francisco; Medical Human Subjects Committee, Stanford University, Stanford, California; Human Subjects Committee, Veterans Affairs Palo Alto Health Care System, Palo Alto, California; and the Data Governance Board of the Community Health Network, San Francisco). All participants provided written informed consent.

GENERALIZED ANXIETY DISORDER

We determined the presence of GAD during the past year using the computerized Diagnostic Interview Schedule for DSM-IV.28 Computerized versions of the Diagnostic Interview Schedule have previously demonstrated acceptable validity and reliability.29,30 We also ascertained the presence of major depressive disorder (MDD) using the computerized Diagnostic Interview Schedule for DSM-IV. Participants with a major depressive episode in the past month were informed of this diagnosis, were instructed to discuss their symptoms with their primary care physician, and were provided a list of local resources available for treatment.

BASELINE CARDIAC DISEASE SEVERITY AND RISK FACTORS

Fasting venous blood samples were collected to determine low- and high-density lipoprotein cholesterol levels. Participants completed an exercise treadmill test according to a standard Bruce protocol. Those who could not continue the standard Bruce protocol were switched to slower settings and were encouraged to exercise for as long as possible. Exercise capacity was calculated as the total number of metabolic equivalent tasks achieved. We performed resting and stress echocardiograms using an ultrasound system (Acuson Sequoia; Acuson Siemens, Mountain View, California) with a 3.5-MHz transducer. Before exercise, standard 2-dimensional parasternal long- and short-axis and apical 2- and 4-chamber views were obtained and planimetered using a computerized digitization system to determine end diastolic and end systolic left ventricular volume and to calculate left ventricular ejection fraction. At peak exercise, parasternal long- and short-axis and apical 2- and 4-chamber views were used to detect the development of left ventricular wall motion abnormalities. Inducible ischemia was defined as the presence of new wall motion abnormalities at peak exercise that were not present at rest.

POTENTIAL BEHAVIORAL MEDIATORS

Smoking and alcohol use were determined by self-report questionnaire.31 To assess medication adherence, we asked, “In the past month, how often did you take your medications as the doctor prescribed?” Possible responses were “all of the time (100%),” “nearly all of the time (90%),” “most of the time (75%),” “about half the time (50%),” or “less than half the time (<50%).” We defined medication nonadherence as taking prescribed medications 75% of the time or less.32 To assess physical activity, we asked, “Which of the following statements best describes how physically active you have been during the past month, that is, done activities such as 15 to 20 minutes of brisk walking, swimming, general conditioning, or recreational sports?” Participants chose 1 of the following 6 categories: not at all active, a little active (1-2 times per month), fairly active (3-4 times per month), quite active (1-2 times per week), very active (3-4 times per week), or extremely active (≥5 times per week). Participants who reported that they were not at all or a little active were considered physically inactive. Self-report has been shown to be a reliable, valid, and accurate method of assessing physical activity.3336 In particular, single-response items have demonstrated excellent construct validity.3537

POTENTIAL BIOLOGICAL MEDIATORS

Three-channel 24-hour ambulatory Holter electrocardiography was used to assess heart rate variability,38 including the standard deviation of 5-minute mean NN intervals (SDANN) and the natural log of very low frequency power. We collected 24-hour urine samples to measure norepinephrine and cortisol excretion. Norepinephrine was assessed by means of gas chromatography–mass spectrometry at Associated Regional and University Pathologists Inc (Salt Lake City, Utah). Cortisol was analyzed using radioimmunoassay or (owing to a change at the Associated Regional and University Pathologists Inc laboratory) high-performance liquid chromatography–tandem mass spectrometry.39,40

We used high-pressure liquid chromatography with electrochemical detection to assay whole-blood serotonin levels.41 High-sensitivity C-reactive protein (CRP) levels were measured using the Integra assay (Roche, Indianapolis, Indiana) in the first 229 participants and (owing to a change at the laboratory) the Extended Range assay (Beckman Coulter Ireland Inc, Galway, Ireland) in the remaining samples.42 Blood levels of 2 ω-3 fatty acids, docosahexaenoic acid and eicosapentaenoic acid, were measured using capillary gas chromatography as the percentage composition of total fatty acid methyl esters in the red blood cell membranes.43

OTHER PATIENT CHARACTERISTICS

Age, sex, race, educational achievement, and medical history were determined by means of self-report questionnaire. We measured height and weight and calculated body mass index (calculated as weight in kilograms divided by height in meters squared). Participants were instructed to bring their medication bottles to their appointment, and study personnel recorded all current medications. Medications were categorized using Epocrates Rx (Epocrates Inc, San Mateo, California).

CARDIOVASCULAR EVENTS

Between the baseline examination and the last day of follow-up on March 18, 2009, we conducted annual follow-up interviews with participants (or their proxies) by telephone asking specifically about hospitalization for “heart trouble.” For any reported event, medical records, electrocardiograms, death certificates, and coroner's reports were retrieved and reviewed by 2 independent blinded adjudicators. In the event of disagreement, the adjudicators conferred, reconsidered their classification, and requested consultation from a third blinded adjudicator as necessary.

The outcome events were stroke, heart failure, myocardial infarction, transient ischemic attack, and death. Heart failure was defined as hospitalization for a clinical syndrome involving at least 2 of the following: orthopnea, third heart sound, pulmonary rales, paroxysmal nocturnal dyspnea, elevated jugular venous pressure, and cardiomegaly or pulmonary edema on chest radiography. These signs and symptoms must have represented a clear change from the usual clinical status.44 Stroke was defined as a new neurologic deficit not known to be secondary to brain trauma, tumor, infection, or another cause.45,46 Nonfatal myocardial infarction was defined based on the presence of symptoms, electrocardiographic changes, and cardiac enzymes using standard criteria.47,48 Transient ischemic attack was defined as a focal neurologic deficit (in the absence of head trauma) lasting more than 30 seconds and no longer than 24 hours, with rapid evolution of the symptoms to the maximal level of deficit in less than 5 minutes and with subsequent complete resolution.45,46 Deaths were confirmed by review of death certificates and coroner's reports.

STATISTICAL ANALYSIS

Baseline differences in characteristics between participants with and without GAD were compared using t tests and χ2 tests. Levels of CRP and ω-3 fatty acid were log transformed because they were not normally distributed. We estimated the risk of cardiovascular events associated with anxiety disorder using Cox proportional hazards models.

To evaluate whether a covariate changed the strength of association between anxiety disorder and cardiovascular events, we calculated the percentage change in the effect size (log hazard ratio [HR]) for anxiety disorder before and after adjustment for the potential confounder or mediator. To avoid any artifact due to different sample sizes between the 2 nested models, participants missing the covariate of interest were excluded from each comparison. We sequentially considered demographic variables, including depression, comorbid conditions, cardiac disease severity, use of medications, and potential behavioral and biological mediators.49 Variables that resulted in a more than 5% change in the effect size (log HR) for GAD were considered confounders or potential mediators and were included in the final multivariable models.50

We verified the proportional hazards assumption of these models using log-minus-log survival plots and by checking for secular patterns in scaled Schoenfeld residuals. We used Wald tests to check for interactions of anxiety disorder with age, sex, and MDD in age- and multivariable-adjusted models. Analyses were performed using a statistical software program (SAS version 9.2; SAS Institute Inc, Cary, North Carolina).

RESULTS

Of the 1015 participants, 106 (10.4%) met the criteria for GAD in the past year. Compared with participants who did not have GAD in the past year, those with GAD were younger, more likely to be female, and more likely to have MDD (Table 1). GAD was associated with a better left ventricular ejection fraction and greater renin-angiotensin system inhibitor, anxiolytic, and antidepressant drug use. Participants with GAD had lower ω-3 fatty acid levels and were more likely to smoke, were less physically active, and were less adherent to medications.

A total of 371 cardiovascular events occurred during 5711 person-years (mean [SD] of 5.6 [1.8] person-years) of follow-up. The age-adjusted annual rate of cardiovascular events was 9.6% in the 106 participants with GAD and 6.6% in the 909 participants without GAD (HR, 1.43; 95% confidence interval [CI], 1.03-2.00; P = .03) (Table 2). After excluding the 222 patients with MDD, the age-adjusted annual rate of cardiovascular events was 9.2% in 21 participants with GAD and 6.9% in 772 participants without GAD (HR, 1.33; 95% CI, 0.69-2.59; P = .39).

POTENTIAL MEDIATORS

Several variables, including male sex, comorbid conditions, left ventricular function, exercise capacity, renin-angiotensin system inhibitor and antidepressant drug use, medication nonadherence, physical activity level, heart rate variability, and CRP level, met the criteria for potential confounding or mediation (Table 3). Variables that did not change the effect size for GAD by 5% or more included MDD, use of selective serotonin reuptake inhibitors or anxiolytics, body mass index, smoking, and levels of serotonin, ω-3 fatty acids, and 24-hour excretion of norepinephrine and cortisol (Table 3).

When adjusted for male sex, comorbid conditions, cardiac disease severity, and medication use, GAD remained associated with a 62% greater rate of cardiovascular events (HR, 1.62; 95% CI, 1.11-2.37; P = .01). Additional adjustment for potential behavioral and biological mediators, including medication nonadherence, physical inactivity, heart rate variability (SDANN), and log CRP level, did not substantially change this association (Table 4). In the final model, GAD was associated with a 74% greater rate of cardiovascular events (HR, 1.74; 95% CI, 1.13-2.67; P = .01) (Table 5 and Figure). We found no evidence that the association between GAD and cardiovascular events varied by age, sex, or MDD (P for interaction ≥ .1 for all).

Given that smoking is a known major cardiovascular risk factor, we conducted a sensitivity analysis by including current smoking in the final model. This did not result in a change in the effect size of GAD. In addition, adjustment for previous smoking did not change the effect of GAD. We conducted a second sensitivity analysis by including left ventricular ejection fraction as a dichotomous variable (as <45% and as <55%) in the final model. This did not result in a significant change in the effect size of GAD.

COMMENT

In this prospective cohort study of more than 1000 outpatients with stable CHD, participants with baseline GAD had a greater rate of subsequent cardiovascular events (stroke, heart failure, myocardial infarction, transient ischemic attack, or death) than did participants without GAD. Despite evaluating a variety of potential mediators, including cortisol, norepinephrine, and CRP levels; heart rate variability; smoking; medication nonadherence; and physical inactivity, the association between GAD and cardiovascular events could not be explained. Even after adjustment for these and other variables, GAD remained associated with a 74% greater rate of cardiovascular events.

This study is unique in its focus on the relationship of GAD to cardiovascular events in outpatients with stable CHD. We are aware of only 1 previous study that has evaluated the cardiac prognostic importance of GAD. Frasure-Smith and Lespérance21 demonstrated that GAD independently predicted cardiac events in 804 patients with acute coronary syndrome, but the extent to which the association was explained by potential behavioral and biological mediators was not assessed. Other studies11,15,1826 examining the impact of anxiety on cardiac prognosis have relied on self-report measurements of anxiety symptoms and have varied in patient populations, sample size, length of follow-up, and ability to control covariates.

We previously found that the association between depressive symptoms and cardiovascular events was largely explained by poor health behaviors, especially physical inactivity, in depressed patients with CHD.28 However, despite an exhaustive search for potential mediators, we did not identify the reason for an increased risk of cardiovascular events associated with anxiety disorder. Several studies have demonstrated that anxiety is linked to pathologic mechanisms involved in CHD events,51 including indicators of autonomic dysfunction, such as reduced baroflex cardiac control and reduced heart rate variability,5255 increased catecholamine levels56 and platelet activity,57 dysregulation of the serotonin system,58 and markers of inflammation and coagulation.59 Thus, we were surprised that biological mediators, such as heart rate variability (SDANN), norepinephrine level, and inflammation (CRP level), did not explain the increased risk associated with anxiety disorder in the present study. Similarly, important health behaviors, including smoking, medication adherence, and physical activity, were not responsible for the increased risk of cardiovascular events.

This leaves the question of why GAD is associated with adverse outcomes in patients with CHD. One possibility is that anxiety may be associated with surges in catecholamines, which are, in turn, related to poor CHD prognosis. Although we collected urine samples to measure levels of catecholamines and found no association with GAD, it is possible that using 24-hour specimens did not allow us to capture these fluctuations. Another possibility is that anxious patients with CHD may be less likely to seek preventive medical care, possibly due to an avoidant coping strategy. Benninghoven et al60 found that patients with higher anxiety levels had worse medication compliance and less contact with their cardiologists. Patients who are less likely to seek preventive care could be at increased risk for subsequent events. Alternatively, patients with anxiety could be more likely to seek care and receive a diagnosis of stroke or myocardial infarction, and, thus, the increased risk of events could be due to greater ascertainment in patients with anxiety. However, this would not explain their increased mortality. It is also possible that there exists a common background origin to GAD symptoms and risk of cardiovascular disease. The interplay of genetic factors or the programming effects of fetal or postnatal growth patterns may play a role. Further research to determine the mechanisms responsible for the relationship between GAD and prognosis is warranted.

We also considered the possibility that depression could have interacted with anxiety and, thus, affected the relationship found between GAD and cardiovascular events. Anxiety and depression are highly comorbid disorders in psychiatric populations and in individuals with chronic medical conditions, including heart disease.6164 In the present study, 80% of patients with GAD had comorbid depressive disorder. However, adjusting for major depression did not change the effect of GAD on cardiovascular events, and we found no evidence of an interaction between GAD and depression. Therefore, the prognostic value of GAD seems to be independent of depressive disorder. This finding is consistent with 2 previous studies11,19 that found anxiety to be a significant predictor of cardiovascular events after adjustment for depression.

Finally, GAD was associated with lower ω-3 fatty acid levels. There is a clear association between dietary factors resulting in lower levels of ω-3 fatty acids and increased CHD risk.65,66 In addition, a recent study43 found a strong association between low ω-3 fatty acid levels and depression in outpatients with stable CHD. Although ω-3 fatty acid levels did not affect the strength of association between GAD and cardiovascular events, this is a potentially interesting avenue to explore.

This study has several strengths, including detailed assessments of GAD and cardiac disease severity, careful measurement of potential behavioral and biological mediators, and comprehensive assessment of cardiovascular events. However, several limitations must also be considered. First, most of the participants were older men, and almost half were recruited from VA medical centers. Therefore, these results may not generalize to women or to other patient populations. Second, the associated risk with GAD may have been the result of greater cardiac disease severity. We attempted to address this possibility by carefully measuring and adjusting for comorbid conditions and cardiovascular disease severity. However, no observational study can completely eliminate confounding, and it remains possible that the effect of GAD on cardiovascular outcomes may have been affected by worse underlying cardiac disease severity that was not otherwise accounted for in the models. Third, this study was limited to outpatients with stable CHD, and, thus, we cannot comment on the mechanisms of association between anxiety and cardiovascular outcomes in healthy populations or in patients after acute coronary syndrome. Fourth, we did not account for other anxiety disorders, such as specific phobias, panic disorder, or posttraumatic stress disorder. In addition, the high comorbidity between GAD and MDD could also mean that minor variants of depression are prevalent that we did not account for in the analyses. Fifth, we had no information on the time frame between the qualifying CHD event and the assessment of GAD except that it was at least 6 months before enrollment.

Despite these limitations, these findings have implications for clinical practice and research. GAD may be considered a prognostic factor in patients with CHD and could be used in risk stratification. Evaluation and treatment of anxiety may also be considered as part of the comprehensive management of patients with CHD. Research programs designed to advance our understanding of the impact of GADs on medical prognosis and biobehavioral mechanisms that link anxiety to mortality in the context of CHD are needed to develop evidence-based approaches to improving patient care. In particular, randomized clinical trials will be necessary to determine whether pharmacologic and behavioral interventions to reduce anxiety will result in better CHD outcomes. The management of anxiety in patients with CHD may also require the development of collaborative and integrative approaches combining medical and psychological expertise.

In summary, we found a strong and robust association between GAD and cardiovascular events that could not be explained by disease severity, health behaviors, or biological mediators. The results of this study indicate the need for future research to identify the underlying processes by which GAD contributes to adverse events in patients with CHD and to test interventions to alleviate this increased risk.

Back to top
Article Information

Correspondence: Elisabeth J. Martens, PhD, Department of Medical Psychology, Tilburg University, Warandelaan 2, PO Box 90153, 5000 LE Tilburg, the Netherlands (e.j.martens@uvt.nl).

Submitted for Publication: July 23, 2009; final revision received December 10, 2009; accepted January 11, 2010.

Author Contributions: Dr Whooley had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Financial Disclosure: None reported.

Funding/Support: This study was supported by the VA Epidemiology (Merit Review) Program; the VA Health Services Research and Development Service Career Development Program; grant R01 HL079235 from the National Heart, Lung, and Blood Institute; the American Federation for Aging Research (Paul Beeson Scholars Program); the Robert Wood Johnson Foundation (Generalist Physician Faculty Scholars Program); the Ischemia Research and Education Foundation; and the Nancy Kirwan Heart Research Fund (all funding to Dr Whooley).

Role of the Sponsors: The funding organizations had no role in the design or conduct of the study; in the collection, management, analysis, or interpretation of the data; or in the preparation, review, or approval of the manuscript.

References
1.
Brotman  DJGolden  SHWittstein  IS The cardiovascular toll of stress. Lancet 2007;370 (9592) 1089- 1100
PubMedArticle
2.
Rosengren  AHawken  SOunpuu  SSliwa  KZubaid  MAlmahmeed  WABlackett  KNSitthi-amorn  CSato  HYusuf  SINTERHEART investigators, Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004;364 (9438) 953- 962
PubMedArticle
3.
Moussavi  SChatterji  SVerdes  ETandon  APatel  VUstun  B Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007;370 (9590) 851- 858
PubMedArticle
4.
Rugulies  R Depression as a predictor for coronary heart disease: a review and meta-analysis. Am J Prev Med 2002;23 (1) 51- 61
PubMedArticle
5.
Wulsin  LRSingal  BM Do depressive symptoms increase the risk for the onset of coronary disease? a systematic quantitative review. Psychosom Med 2003;65 (2) 201- 210
PubMedArticle
6.
Barth  JSchumacher  MHerrmann-Lingen  C Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med 2004;66 (6) 802- 813
PubMedArticle
7.
van Melle  JPde Jonge  PSpijkerman  TATijssen  JGOrmel  Jvan Veldhuisen  DJvan den Brink  RHvan den Berg  MP Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004;66 (6) 814- 822
PubMedArticle
8.
Carney  RMFreedland  KEJaffe  AS Depression as a risk factor for coronary heart disease mortality. Arch Gen Psychiatry 2001;58 (3) 229- 230
PubMedArticle
9.
Denollet  JBrutsaert  DL Personality, disease severity, and the risk of long-term cardiac events in patients with decreased ejection fraction after myocardial infarction. Circulation 1998;97 (2) 167- 173
PubMedArticle
10.
Thombs  BDBass  EBFord  DEStewart  KJTsilidis  KKPatel  UFauerbach  JABush  DEZiegelstein  RC Prevalence of depression in survivors of acute myocardial infarction: review of the evidence. J Gen Intern Med 2006;21 (1) 30- 38
PubMedArticle
11.
Grace  SLAbbey  SEIrvine  JShnek  ZMStewart  DE Prospective examination of anxiety persistence and its relationship to cardiac symptoms and recurrent cardiac events. Psychother Psychosom 2004;73 (6) 344- 352
PubMedArticle
12.
Frasure-Smith  NLespérance  FTalajic  M Depression and 18-month prognosis after myocardial infarction [published correction appears in Circulation. 1998 Feb 24;97(7):708]. Circulation 1995;91 (4) 999- 1005
PubMedArticle
13.
Frasure-Smith  NLespérance  FTalajic  M The impact of negative emotions on prognosis following myocardial infarction: is it more than depression? Health Psychol 1995;14 (5) 388- 398
PubMedArticle
14.
Lane  DCarroll  DRing  CBeevers  DGLip  GY Mortality and quality of life 12 months after myocardial infarction: effects of depression and anxiety. Psychosom Med 2001;63 (2) 221- 230
PubMedArticle
15.
Mayou  RAGill  DThompson  DRDay  AHicks  NVolmink  JNeil  A Depression and anxiety as predictors of outcome after myocardial infarction. Psychosom Med 2000;62 (2) 212- 219
PubMedArticle
16.
Sullivan  MDLaCroix  AZBaum  CGrothaus  LCKaton  WJ Functional status in coronary artery disease: a one-year prospective study of the role of anxiety and depression. Am J Med 1997;103 (5) 348- 356
PubMedArticle
17.
Sullivan  MDLaCroix  ZASpertus  JAHecht  J Five-year prospective study of the effects of anxiety and depression in patients with coronary artery disease. Am J Cardiol 2000;86 (10) 1135- 1138, A6, A9
PubMedArticle
18.
Rothenbacher  DHahmann  HWüsten  BKoenig  WBrenner  H Symptoms of anxiety and depression in patients with stable coronary heart disease: prognostic value and consideration of pathogenetic links. Eur J Cardiovasc Prev Rehabil 2007;14 (4) 547- 554
PubMedArticle
19.
Shibeshi  WAYoung-Xu  YBlatt  CM Anxiety worsens prognosis in patients with coronary artery disease. J Am Coll Cardiol 2007;49 (20) 2021- 2027
PubMedArticle
20.
Moser  DKRiegel  BMcKinley  SDoering  LVAn  KSheahan  S Impact of anxiety and perceived control on in-hospital complications after acute myocardial infarction. Psychosom Med 2007;69 (1) 10- 16
PubMedArticle
21.
Frasure-Smith  NLespérance  F Depression and anxiety as predictors of 2-year cardiac events in patients with stable coronary artery disease. Arch Gen Psychiatry 2008;65 (1) 62- 71
PubMedArticle
22.
Lane  DCarroll  DRing  CBeevers  DGLip  GY Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction. J Psychosom Res 2000;49 (4) 229- 238
PubMedArticle
23.
Lane  DCarroll  DRing  CBeevers  DGLip  GY Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction? QJM 2000;93 (11) 739- 744
PubMedArticle
24.
Lane  DCarroll  DRing  CBeevers  DGLip  GY In-hospital symptoms of depression do not predict mortality 3 years after myocardial infarction. Int J Epidemiol 2002;31 (6) 1179- 1182
PubMedArticle
25.
Ketterer  MWHuffman  JLumley  MAWassef  SGray  LKenyon  LKraft  PBrymer  JRhoads  KLovallo  WRGoldberg  AD Five-year follow-up for adverse outcomes in males with at least minimally positive angiograms: importance of “denial” in assessing psychosocial risk factors. J Psychosom Res 1998;44 (2) 241- 250
PubMedArticle
26.
Herrmann  CBrand-Driehorst  SBuss  URüger  U Effects of anxiety and depression on 5-year mortality in 5057 patients referred for exercise testing. J Psychosom Res 2000;48 (4-5) 455- 462
PubMedArticle
27.
Whooley  MAde Jonge  PVittinghoff  EOtte  CMoos  RCarney  RMAli  SDowray  SNa  BFeldman  MDSchiller  NBBrowner  WS Depressive symptoms, health behaviors, and risk of cardiovascular events in patients with coronary heart disease. JAMA 2008;300 (20) 2379- 2388
PubMedArticle
28.
Robins  LNHelzer  JCroughan  JRatcliff  K National Institute of Mental Health Diagnostic Interview Schedule: its history, characteristics, and validity. Arch Gen Psychiatry 1981;38 (4) 381- 389
PubMedArticle
29.
Greist  JHKlein  MHErdman  HPBires  JKBass  SMMachtinger  PEKresge  DG Comparison of computer- and interviewer-administered versions of the Diagnostic Interview Schedule. Hosp Community Psychiatry 1987;38 (12) 1304- 1311
PubMed
30.
Blouin  AGPerez  ELBlouin  JH Computerized administration of the Diagnostic Interview Schedule. Psychiatry Res 1988;23 (3) 335- 344
PubMedArticle
31.
Dawson  DAGrant  BFStinson  FS The AUDIT-C: screening for alcohol use disorders and risk drinking in the presence of other psychiatric disorders. Compr Psychiatry 2005;46 (6) 405- 416
PubMedArticle
32.
Gehi  AKAli  SNa  BWhooley  MA Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the Heart and Soul Study. Arch Intern Med 2007;167 (16) 1798- 1803
PubMedArticle
33.
Bowles  HRFitzGerald  SJMorrow  JR  JrJackson  AWBlair  SN Construct validity of self-reported historical physical activity. Am J Epidemiol 2004;160 (3) 279- 286
PubMedArticle
34.
Kurtze  NRangul  VHustvedt  BEFlanders  WD Reliability and validity of self-reported physical activity in the Nord-Trondelag Health Study: HUNT 1. Scand J Public Health 2008;36 (1) 52- 61
PubMedArticle
35.
Ainsworth  BEJacobs  DR  JrLeon  AS Validity and reliability of self-reported physical activity status: the Lipid Research Clinics questionnaire. Med Sci Sports Exerc 1993;25 (1) 92- 98
PubMedArticle
36.
Aadahl  MKjaer  MKristensen  JHMollerup  BJørgensen  T Self-reported physical activity compared with maximal oxygen uptake in adults. Eur J Cardiovasc Prev Rehabil 2007;14 (3) 422- 428
PubMedArticle
37.
Jackson  AWMorrow  JR  JrBowles  HRFitzGerald  SJBlair  SN Construct validity evidence for single-response items to estimate physical activity levels in large sample studies. Res Q Exerc Sport 2007;78 (2) 24- 31
PubMedArticle
38.
Gehi  AMangano  DPipkin  SBrowner  WSWhooley  MA Depression and heart rate variability in patients with stable coronary heart disease: findings from the Heart and Soul Study. Arch Gen Psychiatry 2005;62 (6) 661- 666
PubMedArticle
39.
Otte  CMarmar  CRPipkin  SSMoos  RBrowner  WSWhooley  MA Depression and 24-hour urinary cortisol in medical outpatients with coronary heart disease: the Heart and Soul Study. Biol Psychiatry 2004;56 (4) 241- 247
PubMedArticle
40.
Otte  CNeylan  TCPipkin  SSBrowner  WSWhooley  MA Depressive symptoms and 24-hour urinary norepinephrine excretion levels in patients with coronary disease: findings from the Heart and Soul Study. Am J Psychiatry 2005;162 (11) 2139- 2145
PubMedArticle
41.
Wulsin  LRMusselman  DOtte  CBruce  EAli  SWhooley  MA Depression and whole blood serotonin in patients with coronary heart disease from the Heart and Soul Study. Psychosom Med 2009;71 (3) 260- 265
PubMedArticle
42.
Whooley  MACaska  CMHendrickson  BERourke  MAHo  JAli  S Depression and inflammation in patients with coronary heart disease: findings from the Heart and Soul Study. Biol Psychiatry 2007;62 (4) 314- 320
PubMedArticle
43.
Ali  SGarg  SKCohen  BEBhave  PHarris  WSWhooley  MA Association between omega-3 fatty acids and depressive symptoms among patients with established coronary artery disease: data from the Heart and Soul Study. Psychother Psychosom 2009;78 (2) 125- 127
PubMedArticle
44.
Ren  XRistow  BNa  BAli  SSchiller  NBWhooley  MA Prevalence and prognosis of asymptomatic left ventricular diastolic dysfunction in ambulatory patients with coronary heart disease. Am J Cardiol 2007;99 (12) 1643- 1647
PubMedArticle
45.
Asplund  KBonita  RKuulasmaa  KRajakangas  AMSchaedlich  HSuzuki  KThorvaldsen  PTuomilehto  JWorld Health Organization Monitoring Trends and Determinants in Cardiovascular Disease, Multinational comparisons of stroke epidemiology: evaluation of case ascertainment in the WHO MONICA Stroke Study. Stroke 1995;26 (3) 355- 360
PubMedArticle
46.
Thorvaldsen  PAsplund  KKuulasmaa  KRajakangas  AMSchroll  MWorld Health Organization Monitoring Trends and Determinants in Cardiovascular Disease, Stroke incidence, case fatality, and mortality in the WHO MONICA project. Stroke 1995;26 (3) 361- 367
PubMedArticle
47.
Luepker  RVApple  FSChristenson  RHCrow  RSFortmann  SPGoff  DGoldberg  RJHand  MMJaffe  ASJulian  DGLevy  DManolio  TMendis  SMensah  GPajak  APrineas  RJReddy  KSRoger  VLRosamond  WDShahar  ESharrett  ARSorlie  PTunstall-Pedoe  HAHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; National Heart, Lung, and Blood Institute, Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute. Circulation 2003;108 (20) 2543- 2549
PubMedArticle
48.
Thygesen  KAlpert  JSWhite  HDJaffe  ASApple  FSGalvani  MKatus  HANewby  LKRavkilde  JChaitman  BClemmensen  PMDellborg  MHod  HPorela  PUnderwood  RBax  JJBeller  GABonow  RVan der Wall  EEBassand  JPWijns  WFerguson  TBSteg  PGUretsky  BFWilliams  DOArmstrong  PWAntman  EMFox  KAHamm  CWOhman  EMSimoons  MLPoole-Wilson  PAGurfinkel  EPLopez-Sendon  JLPais  PMendis  SZhu  JRWallentin  LCFernández-Avilés  FFox  KMParkhomenko  ANPriori  SGTendera  MVoipio-Pulkki  LMVahanian  ACamm  AJDe Caterina  RDean  VDickstein  KFilippatos  GFunck-Brentano  CHellemans  IKristensen  SDMcGregor  KSechtem  USilber  STendera  MWidimsky  PZamorano  JLMorais  JBrener  SHarrington  RMorrow  DLim  MMartinez-Rios  MASteinhubl  SLevine  GNGibler  WBGoff  DTubaro  MDudek  DAl-Attar  NJoint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Universal definition of myocardial infarction. Circulation 2007;116 (22) 2634- 2653
PubMedArticle
49.
Baron  RMKenny  DA The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51 (6) 1173- 1182
PubMedArticle
50.
Maldonado  GGreenland  S Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138 (11) 923- 936
PubMed
51.
Grippo  AJJohnson  AK Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002;26 (8) 941- 962
PubMedArticle
52.
Thayer  JFFriedman  BHBorkovec  TD Autonomic characteristics of generalized anxiety disorder and worry. Biol Psychiatry 1996;39 (4) 255- 266
PubMedArticle
53.
Martens  EJNyklícek  ISzabó  BMKupper  N Depression and anxiety as predictors of heart rate variability after myocardial infarction. Psychol Med 2008;38 (3) 375- 383
PubMed
54.
Watkins  LLBlumenthal  JACarney  RM Association of anxiety with reduced baroreflex cardiac control in patients after acute myocardial infarction. Am Heart J 2002;143 (3) 460- 466
PubMedArticle
55.
Cohen  HBenjamin  J Power spectrum analysis and cardiovascular morbidity in anxiety disorders. Auton Neurosci 2006;128 (1-2) 1- 8
PubMedArticle
56.
Cameron  OGNesse  RM Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology 1988;13 (4) 287- 307
PubMedArticle
57.
Cameron  OGSmith  CBLee  MAHollingsworth  PJHill  EMCurtis  GC Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 1990;28 (1) 3- 20
PubMedArticle
58.
Williams  RBMarchuk  DAGadde  KMBarefoot  JCGrichnik  KHelms  MJKuhn  CMLewis  JGSchanberg  SMStafford-Smith  MSuarez  ECClary  GLSvenson  IKSiegler  IC Central nervous system serotonin function and cardiovascular responses to stress. Psychosom Med 2001;63 (2) 300- 305
PubMedArticle
59.
Pitsavos  CPanagiotakos  DBPapageorgiou  CTsetsekou  ESoldatos  CStefanadis  C Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis 2006;185 (2) 320- 326
PubMedArticle
60.
Benninghoven  DKaduk  AWiegand  USpecht  TKunzendorf  SJantschek  G Influence of anxiety on the course of heart disease after acute myocardial infarction: risk factor or protective function? Psychother Psychosom 2006;75 (1) 56- 61
PubMedArticle
61.
Zimmerman  MMcDermut  WMattia  JI Frequency of anxiety disorders in psychiatric outpatients with major depressive disorder. Am J Psychiatry 2000;157 (8) 1337- 1340
PubMedArticle
62.
Katon  WLin  EHBKroenke  K The association of depression and anxiety with medical symptom burden in patients with chronic medical illness. Gen Hosp Psychiatry 2007;29 (2) 147- 155
PubMedArticle
63.
Aina  YSusman  JL Understanding comorbidity with depression and anxiety disorders. J Am Osteopath Assoc 2006;106 (5) (suppl 2)S9- S14
PubMed
64.
Walke  LMByers  ALGallo  WTEndrass  JFried  TR The association of symptoms with health outcomes in chronically ill adults. J Pain Symptom Manage 2007;33 (1) 58- 66
PubMedArticle
65.
Marchioli  RBarzi  FBomba  EChieffo  CDi Gregorio  DDi Mascio  RFranzosi  MGGeraci  ELevantesi  GMaggioni  APMantini  LMarfisi  RMMastrogiuseppe  GMininni  NNicolosi  GLSantini  MSchweiger  CTavazzi  LTognoni  GTucci  CValagussa  FGISSI-Prevenzione Investigators, Early protection against sudden death by n–3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI) – prevenzione. Circulation 2002;105 (16) 1897- 1903
PubMedArticle
66.
Yokoyama  MOrigasa  HMatsuzaki  MMatsuzawa  YSaito  YIshikawa  YOikawa  SSasaki  JHishida  HItakura  HKita  TKitabatake  ANakaya  NSakata  TShimada  KShirato  KJapan EPA Lipid Intervention Study (JELIS) Investigators, Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis [published correction appears in Lancet. 2007;370(9583):220]. Lancet 2007;369 (9567) 1090- 1098
PubMedArticle
×